Background:
Emergence of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) infection has given
rise to COVID-19 pandemic, that is wreaking havoc worldwide. Therefore, there is an urgent need to find out novel drugs to
combat SARS-CoV-2 infection. In this backdrop, the present study was aimed to assess potent bioactive compounds from
different fungi as potential inhibitors of SARS-CoV-2 main protease (Mpro) using an in-silico analysis.
Methods:
Resolution Liquid Chromatography Mass Spectrometry analysis (HR-LCMS) was used for the bioactive profiling
of ethanolic crude extract of Dictyophora indusiata, Geastrum triplex and Cyathus stercoreus. Of which, only bergenin (D.
indusiata), quercitrin (G. triplex) and dihydroartemisinin (C. stercoreus) were selected based on their medicinal uses,
binding score and active site covered. The 6LU7, a protein crystallographic structure of SARS-CoV-2 Mpro, was docked
with bergenin, quercitrin and dihydroartemisinin using Autodock 4.2.
Results:
Total 118 bioactive compounds were analyzed from the crude extract of used fungi and identified using HR LC/MS
analysis. The binding energies obtained were -7.86, -10.29 and -7.20 kcal/mol, respectively after docking analysis.
Bergenin, quercitrin and dihydroartemisinin formed hydrogen bond, electrostatic interactions and hydrophobic interactions
with foremost active site amino acids THR190, GLU166, GLN189, GLY143, HIS163, HIS164, CYS145 and PHE140.
Conclusion:
Present investigation suggests that these three compounds may be used as alternative inhibitors against SARSCoV-2 Mpro. However, further research is necessary to assess in vitro potential of these compounds. To the best of our
knowledge, present investigation reported these three bioactive compounds of fungal origin for the first time.